339 related articles for article (PubMed ID: 1424043)
1. Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Chesebro JH; Webster MW; Zoldhelyi P; Roche PC; Badimon L; Badimon JJ
Circulation; 1992 Dec; 86(6 Suppl):III100-10. PubMed ID: 1424043
[TBL] [Abstract][Full Text] [Related]
2. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L
Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304
[TBL] [Abstract][Full Text] [Related]
3. Prevention of cardiovascular events after acute coronary syndrome.
Wallentin L
Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
[TBL] [Abstract][Full Text] [Related]
4. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
6. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
Buchanan MR; Brister SJ
Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889
[TBL] [Abstract][Full Text] [Related]
7. [Significance of coronary thrombosis for chronic myocardial ischemia].
Schoebel FC; Gradaus F; Jax TW; Stiegler HM; Stein DA; Borries M; Kelm M; Strauer BE; Leschke M
Z Kardiol; 1997; 86 Suppl 1():71-83. PubMed ID: 9173723
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction.
Becker RC
Arch Pathol Lab Med; 1993 Jan; 117(1):89-96. PubMed ID: 8418769
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs.
Lam JY; Chesebro JH; Steele PM; Heras M; Webster MW; Badimon L; Fuster V
Circulation; 1991 Aug; 84(2):814-20. PubMed ID: 1830520
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
11. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
[TBL] [Abstract][Full Text] [Related]
12. Atherosclerotic plaque rupture and thrombosis. Evolving concepts.
Fuster V; Stein B; Ambrose JA; Badimon L; Badimon JJ; Chesebro JH
Circulation; 1990 Sep; 82(3 Suppl):II47-59. PubMed ID: 2203564
[TBL] [Abstract][Full Text] [Related]
13. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
14. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
15. The use of antithrombotic drugs in artery disease.
Gallus AS
Clin Haematol; 1986 May; 15(2):509-59. PubMed ID: 3524934
[TBL] [Abstract][Full Text] [Related]
16. [Coronary thrombosis--an old concept in a new light].
Baur HR
Schweiz Rundsch Med Prax; 1992 Sep; 81(39):1147-51. PubMed ID: 1410998
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1997 Jul; 78(1):736-41. PubMed ID: 9198248
[TBL] [Abstract][Full Text] [Related]
18. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
[TBL] [Abstract][Full Text] [Related]
19. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
Gold HK; Yasuda T; Jang IK; Guerrero JL; Fallon JT; Leinbach RC; Collen D
Circulation; 1991 Jun; 83(6 Suppl):IV26-40. PubMed ID: 2040069
[TBL] [Abstract][Full Text] [Related]
20. [Antithrombin therapy in acute coronary syndromes].
Maseri A; Andreotti F; Biasucci LM; Rebuzzi AG
Cardiologia; 1994 Dec; 39(12 Suppl 1):7-13. PubMed ID: 7634317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
